Document Detail

Anti-angiogenic effects of liposomal prednisolone phosphate on B16 melanoma in mice.
MedLine Citation:
PMID:  16707187     Owner:  NLM     Status:  MEDLINE    
Prednisolone phosphate (PLP) encapsulated in long-circulating liposomes can inhibit tumor growth after intravenous administration (i.v.). These antitumor effects of liposomal PLP are the result of the tumor-targeting property of the liposome formulation. The mechanism by which liposomal PLP inhibits tumor growth is unclear. We investigated the effects of liposome-encapsulated PLP versus free PLP on angiogenic protein production in tumor tissue in vivo and on viability and proliferation of tumor and endothelial cells in vitro. In vivo, liposomal PLP had a stronger reducing effect on pro-angiogenic protein levels than free PLP, whereas levels of anti-angiogenic proteins were hardly affected. Cell viability was only slightly affected with either treatment. Liposomal PLP had strong anti-proliferative effects on human umbilical vein endothelial cells, whereas free PLP had hardly any effect. Taken together, the present study points to a strong inhibitory effect of liposomal PLP on tumor angiogenesis by reduction of the intratumoral production of the majority of pro-angiogenic factors studied and direct inhibition of endothelial cell proliferation, which is the result of high prolonged levels of prednisolone in the tumor by liposomal delivery.
Manuela Banciu; Raymond M Schiffelers; Marcel H A M Fens; Josbert M Metselaar; Gert Storm
Related Documents :
25060607 - Pigmented onychomatricoma: a rare pigmented nail unit tumor presenting as longitudinal ...
23018247 - Clinicopathologic features of molecular subtypes of triple negative breast cancer based...
24777267 - Renal carcinoid tumor metastatic to the uvea, medial rectus muscle, and the contralater...
24134767 - Anaplastic sarcoma of the kidney: case report and literature review.
16084457 - Pulmonary large cell carcinoma with rhabdoid phenotype.
11777617 - Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/...
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't     Date:  2006-04-07
Journal Detail:
Title:  Journal of controlled release : official journal of the Controlled Release Society     Volume:  113     ISSN:  0168-3659     ISO Abbreviation:  J Control Release     Publication Date:  2006 Jun 
Date Detail:
Created Date:  2006-06-12     Completed Date:  2006-08-25     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8607908     Medline TA:  J Control Release     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  1-8     Citation Subset:  IM    
Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, The Netherlands.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Cell Line, Tumor
Cell Proliferation / drug effects
Cell Survival / drug effects
Cells, Cultured
Colonic Neoplasms / drug therapy,  metabolism,  pathology,  prevention & control
Drug Delivery Systems
Endothelium, Vascular / drug effects
Injections, Intravenous
Melanoma, Experimental / blood supply*,  pathology,  prevention & control*
Mice, Inbred C57BL
Neovascularization, Pathologic / prevention & control*
Prednisolone / administration & dosage,  analogs & derivatives*,  therapeutic use
Time Factors
Umbilical Veins / cytology
Reg. No./Substance:
0/Liposomes; 302-25-0/prednisolone phosphate; 50-24-8/Prednisolone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Using TEM to couple transient protein distribution and release for PLGA microparticles for potential...
Next Document:  Aminated gelatin microspheres as a nasal delivery system for peptide drugs: evaluation of in vitro r...